Goldman Sachs, Jefferies and UBS are mandated to lead the syndicated debt financing for the Lone Star-led CHF2.3 billion ...

Lonza is at long last shedding its capsules and health ingredients (CHI) business in a private equity sale that could see proceeds of 3 billion Swiss francs ($4 billion) or more.  | Under the deal ...

Lonza has entered into a definitive agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds ...

The Swiss firm is selling its capsules and health ingredients business to Lone Star Funds for CHF2.3 billion ($3 billion).

Lone Star has entered into a definitive agreement to acquire the Capsules and Health Ingredients division of Lonza Group. Lonza will retain a 40 percent equity position in the business. Headquartered ...

Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), and Genetix Biotherapeutics ...

Will expand manufacturing capacity at Lonza’s Houston facility to support growing demand for Genetix’s ZYNTEGLO ...

March 6 (Reuters) - Lonza will sell its capsules and health ingredients business to private equity firm Lone Star Funds for an enterprise value of 2.3 billion Swiss francs ($3.0 billion), the Swiss ...

The Switzerland‑based company finalized its decision after months of evaluation and discussions with state leadership.

Octane Medical Group ("Octane") today announced that it has entered into a definitive agreement to acquire Lonza's Personalized Medicine business. For Octane, this is a strategically significant deal ...

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing ...

Hyderabad: Swiss contract development and manufacturing organisation (CDMO) player Lonza Group AG has zeroed in on Hyderabad ...